Cytiva Pipe dream to pipeline WP 3
Artiva doses first subject in Phase I lupus nephritis treatment trial
The multi-centre, open-label trial aims to evaluate the safety and clinical activity of AlloNK along with monoclonal antibodies in LN patients.